Published in Genetics and Environmental Business Week, March 13th, 2008
One of these agreements is for the conjoint clinical development of aerosolized AAT for treating the indications of Cystic Fibrosis (CF) and Bronchiectasis, in addition to Alpha-1 Antitrypsin Deficiency (AATD). Under the agreement PARI grants Kamada an exclusive license to use an optimized eFlow(R) Electronic Nebulizer to deliver AAT in its clinical trials also for these indications.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week